DILI and drug development: a regulatory perspective

Mark I Avigan1

  • 1Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland.

Insights

Predicting rare, serious drug-induced liver injury (DILI) requires analyzing pre- and postmarket data. Rigorous monitoring and analysis are key to identifying hepatotoxic drugs and susceptible individuals.

Area of Science:

  • Pharmacovigilance
  • Hepatotoxicity
  • Drug Safety

Background:

  • Serious drug-induced liver injury (DILI) is rare but life-threatening.
  • Predicting DILI risk from clinical trials is challenging due to data limitations.
  • Identifying drugs causing idiosyncratic DILI is crucial for public health.

Purpose of the Study:

  • To outline strategies for assessing DILI risk using pre- and postmarket data.
  • To emphasize the importance of rigorous data collection and causality analysis for DILI cases.
  • To highlight the need for improved predictive tools in drug development.

Main Methods:

  • Iterative analysis of pre- and postmarket datastreams.
  • Identification of cases consistent with Hy's law.
  • Rigorous standards in subject monitoring and liver injury case analysis.

Main Results:

  • Current methods rely on analyzing available data streams.
  • Hy's law criteria aid in identifying potential hepatotoxic drugs.
  • Adherence to rigorous standards is essential for accurate DILI assessment.

Conclusions:

  • Accurate DILI risk assessment depends on robust data analysis and monitoring.
  • Future predictive tools will enhance the identification of hepatotoxic agents.
  • Identifying susceptible individuals is key to preventing serious DILI.

Related Concept Videos

Drug Regulation01:25

Drug Regulation

Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
3.0K
Drug Toxicity: Overview01:00

Drug Toxicity: Overview

Drug toxicity quantifies the harm a compound causes to an organism, varying by dose and potentially impacting whole systems or specific organs like the liver. Toxic reactions may arise from venomous insect or spider bites, with effects ranging from mild symptoms to severe outcomes such as brain damage or death. Common forms of acute poisoning include ethanol intoxication and overdose of pain or fever medications, with substances like GHB and heroin being particularly lethal at doses close to...
291
Drug Toxicity: Dose-Dependent Reactions01:24

Drug Toxicity: Dose-Dependent Reactions

Drug toxicities can be stratified into pharmacological, pathological, or genotoxic based on their mechanisms. The incidence and severity of these toxicities generally increase with the drug's concentration in the body and exposure time.Pharmacological toxicity is evident when the therapeutic effects of drugs overshoot into adverse reactions in a predictable, dose-dependent manner. Central nervous system (CNS) depression from barbiturates is a classic example, with effects escalating from...
229
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
271
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
382
Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug01:14

Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug

In pharmacotherapy, monitoring drug concentrations is paramount, especially for drugs whose therapeutic effects hinge on both the active compound and its metabolite. Hepatic impairment profoundly influences drug potency by altering liver function. If the drug is more potent than its metabolite, impaired liver function amplifies drug activity due to elevated drug concentration levels. Conversely, if the metabolite holds greater potency, diminished liver function diminishes drug activity by...
357